Fig. 5: Reactogenicity after primary and secondary vaccination with homologous and heterologous COVID-19 vaccine regimens. | Nature Communications

Fig. 5: Reactogenicity after primary and secondary vaccination with homologous and heterologous COVID-19 vaccine regimens.

From: Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens

Fig. 5

According to their COVID-19 vaccine regimens, individuals were classified into three groups after dose 1 (ChAdOx vector (n = 229), BNT (n = 43) or mRNA-1273 vaccine (n = 58)) and five groups after dose 2 (homologous: ChAdOx/ChAdOx, n = 62; BNT/BNT, n = 43; mRNA-1273/mRNA-1273, n = 58; heterologous: ChAdOx/BNT, n = 66; ChAdOx/mRNA-1273, n = 101). Self-reported reactogenicity within the first week after each vaccine dose was assessed using a standardized questionnaire. The presence of local or systemic adverse events in general (a), substantial local (b) or systemic adverse events (c), and individual perception of which of the two vaccinations affected more (d) are shown. Statistical analyses of differences between the groups after the first and the second vaccination are shown in Supplementary Tables 2 and 3. Source data are provided as a Source Data file.

Back to article page